Inhibitors in nonsevere haemophilia A: Outcome and eradication strategies

Thrombosis and Haemostasis

Volumn 114, Issue 1, 2015, Pages 46-55

  Vanvelzen, Alice S ^a   Eckhardt, Corien L ^a,b   Hart, Daniel P ^c   Peters, Marjolein ^a   Rangarajan, Savita ^d   Mancuso, Maria Elisa ^e   Smiers, Frans J ^f   Khair, Kate ^g   Petrini, Pia ^h   Jimenez Yuste, Victor ⁱ   Hay, Charles R M ^j   van der Bom, Johanna G ^f   Yee, Thynn T ^k   Fijnvandraat, Karin ^a  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^k ROYAL FREE HOSPITAL   (United Kingdom)

more..

Author keywords

Eradication treatment; Factor VIII inhibitors; Haemophilia A; Immune tolerance induction

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR; CYCLOPHOSPHAMIDE; PREDNISONE; RITUXIMAB; ANTIBODY; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 8; F8 PROTEIN, HUMAN; HEMOSTATIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CHILD; DISEASE ERADICATION; DISEASE SEVERITY; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; HEMOPHILIA A; HEMOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; TREATMENT PLANNING; ADOLESCENT; AUSTRALIA; BLOOD; CLINICAL TRIAL; DESENSITIZATION; EUROPE; HEMORRHAGE; IMMUNOLOGY; MIDDLE AGED; PRESCHOOL CHILD; PROCEDURES; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES; BIOMARKERS; CHILD; CHILD, PRESCHOOL; DESENSITIZATION, IMMUNOLOGIC; EUROPE; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HEMOSTATICS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; SOUTH AUSTRALIA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84934783767     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-11-0940     Document Type: Article

References (22)

1. Fijnvandraat K, Cnossen MH, Leebeek FW, et al. Diagnosis and management of haemophilia. Br Med J 2012; 344: e2707.
2. Eckhardt CL, van Velzen AS, Peters M, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in non-severe haemophilia A. Blood 2013; 122: 1954.
3. Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate- severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-766.
4. Peerlinck K, Jacquemin M. Mild haemophilia: a disease with many faces and many unexpected pitfalls. Haemophilia 2010; 16 (Suppl 5): 100-106.
5. Morfini M, Haya S, Tagariello G, et al. European study on orthopaedic status of haemophilia patients with inhibitors. Haemophilia 2007; 13: 606-612.
6. Darby SC, Keeling DM, Spooner RJ, et al. The incidence of factor VIII and factor IX inhibitors in the haemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-1054.
7. Wight J, Paisley S, Knight C. Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 436-463.
8. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors--twenty years' 'bonn protocol'. Vox Sang 1996; 70 (Suppl 1): 30-35.
9. Freiburghaus C, Berntorp E, Ekman M, et al. Tolerance induction using the Malmö treatment model 1982-1995. Haemophilia: the official journal of the World Federation of Haemophilia 1999; 5: 32-39.
10. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, et al. Low-dose immune tolerance induction in haemophilia A patients with inhibitors. Blood 1995; 86: 983-988.
11. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with haemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-950.
12. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 1999; 77 (Suppl 1): 49-54.
13. Van Leeuwen EF, Mauser-Bunschoten EP, Van Dijken PJ, et al. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose. Br J Haematol 1986; 64: 291-297.
14. Hay CR, Dimichele DM. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-1344.
15. Collins PW. Novel therapies for immune tolerance in haemophilia A. Haemophilia 2006; 12: 94-101.
16. Franchini M, Mengoli C, Lippi G, et al. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis. Haemophilia 2008; 14: 903-912.
17. Di Michele DM. Immune tolerance induction in haemophilia: evidence and the way forward. J Thromb Haemost 2011; 9 (Suppl 1): 216-225.
18. Saint-Remy JM, Lacroix-Desmazes S, Oldenburg J. Inhibitors in haemophilia: pathophysiology. Haemophilia 2004; 10 (Suppl 4): 146-151.
19. Kasper CK, Aledort L, Aronson D, et al. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
20. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-251.
21. Kempton CL, Allen G, Hord J, et al. Eradication of factor viii inhibitors in patients with mild and moderate haemophilia A. Am J Hematol 2012; 87: 933-936.
22. Collins PW, Chalmers E, Hart DP, et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160: 153-170.